Use of antiretroviral therapy in pregnancy and association with birth outcome among women living with HIV in Denmark: A nationwide, population‐based cohort study
Open Access
- 6 April 2022
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 23 (9) , 1007-1018
Abstract
Objective: To describe antiretroviral therapy (ART) regimens during pregnancy among women living with HIV (WLWH) in Denmark and to examine the association between ART use in pregnancy and adverse birth outcomes.Methods: A population‐based cohort study including all pregnancies among WLWH in Denmark between 2000 and 2019. Data were collected through national registries. Temporal trends of ART use in pregnancy were evaluated. Logistic regression models were used to examine the association of ART use in pregnancy and other risk factors with adverse birth outcomes.Results: In total, 589 pregnancies were included. Combination treatment with a nucleoside reverse transcriptase inhibitor (NRTI) and a protease inhibitor (PI) was the most common ART regimen (96%). ART regimen, PI use in pregnancy and timing of ART initiation were not significantly associated with increased odds of preterm birth, small for gestational age or low birth weight. First‐trimester initiation of ART was significantly associated with increased odds of intrauterine growth restriction in the multivariate analysis [adjusted odds ratio (aOR) = 3.78, 95% confidence interval (CI): 1.23–11.59], while first trimester PI use was associated with increased odds of IUGR in the univariate analysis only [OR = 3.24, 95% CI: 1.13–9.30]. Smoking, comorbidity, and maternal HIV RNA ≥ 50 copies/mL were independently associated with increased odds of adverse birth outcomes.Conclusions: Pregnant WLWH living in Denmark are generally well treated with HIV RNA < 50 copies/mL at delivery and NRTI + PI as the most common ART regimen used in pregnancy. Initiation of ART in the first trimester may be associated with poor fetal growth. The association between ART use in pregnancy and adverse birth outcomes may partly be explained by maternal risk factors.Keywords
Funding Information
- Aase og Ejnar Danielsens Fond
This publication has 43 references indexed in Scilit:
- Premature Delivery in HIV-Infected Women Starting Protease Inhibitor Therapy During Pregnancy: Role of the Ritonavir Boost?Clinical Infectious Diseases, 2012
- Incidence, Patterns, and Predictors of Repeat Pregnancies Among HIV-Infected Women in the United Kingdom and Ireland, 1990–2009JAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Safety of efavirenz in the first trimester of pregnancyAIDS, 2011
- Impact of Non-HIV and HIV Risk Factors on Survival in HIV-Infected Patients on HAART: A Population-Based Nationwide Cohort StudyPLOS ONE, 2011
- The Danish National Patient RegisterScandinavian Journal of Public Health, 2011
- The Danish Civil Registration SystemScandinavian Journal of Public Health, 2011
- Antiretroviral therapy and preterm delivery—a pooled analysis of data from the United States and EuropeBJOG: An International Journal of Obstetrics & Gynaecology, 2010
- Is Antiretroviral Therapy during Pregnancy Associated with an Increased Risk of Preterm Delivery, Low Birth Weight, or Stillbirth?The Journal of Infectious Diseases, 2006
- Antiretroviral Therapy during Pregnancy and the Risk of an Adverse OutcomeNew England Journal of Medicine, 2002
- Smoking in pregnancyCurrent Opinion in Obstetrics and Gynecology, 2002